Acromegaly News and Research

RSS
Acromegaly is a syndrome that results when the pituitary gland produces excess growth hormone (hGH) after epiphyseal plate closure at puberty.
Endocrine Society’s new Scientific Statement offers guidance to spot hormonal causes of hypertension

Endocrine Society’s new Scientific Statement offers guidance to spot hormonal causes of hypertension

FDA accepts Chiasma's NDA filing for octreotide capsules for treatment of adult patients with acromegaly

FDA accepts Chiasma's NDA filing for octreotide capsules for treatment of adult patients with acromegaly

Chiasma closes $70 million Series E financing round

Chiasma closes $70 million Series E financing round

Chiasma announces publication of octreotide capsules Phase III study results in JCEM

Chiasma announces publication of octreotide capsules Phase III study results in JCEM

Chromosome X microduplications implicated in infancy-onset gigantism

Chromosome X microduplications implicated in infancy-onset gigantism

Novartis announces FDA approval of Signifor LAR for treatment of patients with acromegaly

Novartis announces FDA approval of Signifor LAR for treatment of patients with acromegaly

New Clinical Practice Guideline for diagnosis, treatment of acromegaly

New Clinical Practice Guideline for diagnosis, treatment of acromegaly

ANP reports primary efficacy results from ATL1103 Phase II trial in patients with acromegaly

ANP reports primary efficacy results from ATL1103 Phase II trial in patients with acromegaly

Acromegaly and antisense therapy: an interview with Mark Diamond, CEO Antisense Therapeutics

Acromegaly and antisense therapy: an interview with Mark Diamond, CEO Antisense Therapeutics

Glide Pharma announces successful completion of pre-clinical proof-of-concept study with novel solid formulation of octreotide acetate

Glide Pharma announces successful completion of pre-clinical proof-of-concept study with novel solid formulation of octreotide acetate

Ipsen’s Somatuline CLARINET Phase III study published online in NEJM

Ipsen’s Somatuline CLARINET Phase III study published online in NEJM

Ipsen seeks marketing authorization from FDA for Somatuline Depot 120mg injection

Ipsen seeks marketing authorization from FDA for Somatuline Depot 120mg injection

Ipsen submits Supplemental New Drug Application to FDA for Somatuline Depot 120mg injection

Ipsen submits Supplemental New Drug Application to FDA for Somatuline Depot 120mg injection

Novartis presents Phase III results of Signifor LAR therapy in patients with acromegaly

Novartis presents Phase III results of Signifor LAR therapy in patients with acromegaly

Antisense Therapeutics enrolls acromegalic patients in ATL1103 Phase II trial

Antisense Therapeutics enrolls acromegalic patients in ATL1103 Phase II trial

Aradigm reports record revenue of $4.6M in fourth quarter 2013

Aradigm reports record revenue of $4.6M in fourth quarter 2013

ANP reports positive interim results from ATL1103 Phase II clinical trial for acromegaly

ANP reports positive interim results from ATL1103 Phase II clinical trial for acromegaly

Drugs often fail to bring acromegaly under control in routine clinical practice

Drugs often fail to bring acromegaly under control in routine clinical practice

Chiasma, Roche enter agreement to develop and commercialize Octreolin

Chiasma, Roche enter agreement to develop and commercialize Octreolin

FDA approves Novartis Signifor injection for treatment of Cushing's disease

FDA approves Novartis Signifor injection for treatment of Cushing's disease